Endeavor

New Drug Duo Significantly Slows Progression of Aggressive Breast Cancer

Phase 3 trial shows sacituzumab govitecan and pembrolizumab outperform standard treatment in triple-negative breast cancer

Researchers Explore New Treatment for Aggressive Head and Neck Cancer

Early clinical trial results suggest dual drug therapy may improve survival for patients with HPV-negative head and neck cancer

New Oral Drug Shows Promise for Patients with HER2-Mutated Lung Cancer

Beamion LUNG-1 trial results highlight zongertinib’s strong tumor control and durable responses

Can Immunotherapy Spare Certain Patients From Surgery?

Dostarlimab offers organ preservation and better quality of life for patients with mismatch repair-deficient tumors

Experimental Drug Shows Promise for Patients With Rare Lung Cancer Mutation

New drug targets active form of KRAS, offering hope for lung cancer patients

Moffitt Study Uncovers a Way To Boost Treatment for Aggressive Melanoma

Combination treatment triggers immune response and limits tumor growth

Moffitt Launches Immunotherapy Podcast

Monthly series highlights visionaries in immunotherapy and the breakthroughs that are transforming lives

Moffitt Study Shows New Immune Boost Could Expand Access to Cancer Immunotherapy

Adding a natural protein improves the speed and success of TIL manufacturing, potentially benefiting more patients

Imaging Innovations Could Lead to Better Kidney Cancer Treatment

New technology is helping researchers understand how kidney cancer evades the immune system